South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, September 26, 2025
1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Matthew Stanley, DO	-
Bill Ladwig, RPh	X	Brandi Tackett, PharmD	-
Sarah McGill, PharmD	X	Deidra Van Gilder, PharmD, Chair	X
Jesse Nieuwenhuis, MD	X	Clarissa Barnes, MD, DSS Staff	X
Kelley Oehlke, PharmD	X	Mike Jockheck, DSS Staff	X
Heather Preuss, MD	-	Taylor Koerner, DSS Staff	X

Administrative Business

Van Gilder called the meeting to order at 1:01 pm. Jockheck announced Stanley will be stepping down. The minutes of the June meeting were presented. Baack made a motion to approve. Oehlke seconded the motion. The motion to approve the minutes was approved unanimously.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from April 1, 2025, to June 30, 2025. A total of 4,230 PAs were reviewed of which 121 requests (2.6%) were received via telephone, 109 requests (2.9%) were received via fax, 1,559 requests (36.8%) were reviewed electronically, and 2,441requests (57.7%) were received via ePA. There was a 7% decrease in PAs received compared to the previous quarter. There was a 5.6% increase in number of appeals. Baack inquired about Dexcom

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from April 1, 2025, to June 30, 2025. The top five therapeutic classes based on paid amount were atypical antipsychotics, immunomodulator agents, incretin mimetics, interleukin-mediated agents, and tumor necrosis factor inhibitors. These top 15 therapeutic classes comprise 18.3% of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid constitute 7.48% of total claims. Vykat XR made its debut on the Top 50 drug list by paid amount.

Old Business

CGRP oral and SubQ review

Committee reviewed utilization of members taking both oral and SubQ CGRP medication. Most members were taking as preventative and as acute treatment. Jockheck will coordinate with DUR vendor to educate prescribers on the members taking duplicate therapy. Jasmine Inman, Field Value Evidence and Outcomes pharmacist at Teva, provided public comment.

Antipsychotics review

Committee reviewed the new biometric screening criteria on the Atypical Antipsychotic PA. Providing the biometric screening information will start on 1/1/2026 but will be mandatory effective 1/1/2027. Baack provided perspective on the hurdles of obtaining blood pressure and blood work on severely autistic

children. Jockheck discussed options for these patients. Baack asked for an exemption or physician attestation for these members. Barnes added that providers had shared in the difficulty of obtaining labs for autism patients, however they agreed on the importance of obtaining biometric screening information on all patients. Metrics such as finger sticks for A1C and glucose to ease the screening for these patients were discussed. Aaron Feyos, Director of Health Economics and Outcomes at Bristol Myers, Squibb provided public comment.

Opioid Update
The committee reviewed opioid outcomes compared to the previous quarter from the opioid initiatives. There was an increase in opioid utilization and utilizers during 2Q2025. The average MME/day/utilizer stayed steady.

New Business

Stelara and biosimilars review
Committee reviewed utilization of ustekinumab and discussed preferred products. McGill asked about keeping patients who have been historically hard to treat on the reference product. Jockheck replied each patient would need to be assessed and would be similar to DAW 1 policy. Jasmine Inman provided public comment. Baack made a motion of trial and failure of biosimilar preferred product before Stelara. Ladwig seconded the motion. The motional approved unanimously.

Oxervate
Committee reviewed Oxervate utilization and member diagnosis. Van Gilder inquired if there was any public comment. There was none. Ladwig made a motion to adopt State A criteria. McGill seconded the motion. Motion approved unanimously.

Cholbam
Committee reviewed Cholbam utilization and member diagnoses. Van Gilder and Ladwig commented utilization looked appropriate for the population. Van Gilder inquired if there was any public comment. There was none.

Promacta
Committee reviewed Promacta utilization and member diagnoses. Baack commented utilization is appropriately prescribed for members reviewed and PA not necessary. Ladwig agreed. Van Gilder inquired if there was any public comment. There was none.

Symbravo
Symbravo clinical information was presented for review. Ladwig also commented on utilization of meloxicam capsules. Van Gilder inquired if there was any public comment. There were none. Baack made a motion to adopt State B and commercial PA criteria. Ladwig seconded the motion. The motion was approved unanimously. Ladwig also made a motion to add PA criteria of dysphagia to meloxicam capsules. Baack seconded the motion. The motion was approved unanimously.

Adjournment
The next meeting is scheduled for December 12, 2025. The March and June meetings are tentatively scheduled for March 27, 2026, and June 12, 2026. All motioned and were in favor of adjourning the meeting. The meeting adjourned at 2:17 pm CT.